文献速递外周动脉疾病血液透析通路

血管闭合装置顺行使用的并发症率:系统评价与汇总分析

Complication rates associated with antegrade use of vascular closure devices: a systematic review and pooled analysis.
PubMed 文献 · J Vasc Surg · 2020-09-17

该系统评价纳入24项研究、4124例血管闭合事件,比较6种血管闭合装置在顺行股总动脉与股浅动脉介入中的并发症率。汇总并发症率在股总动脉为0.9%至7.4%,股浅动脉为0%至10.1%,装置间出血并发症率差异显著,但股总动脉与股浅动脉入路间总体并发症率和出血率无差异。

要点

  • 不同血管闭合装置间出血并发症率存在显著差异,但研究间异质性高需谨慎解读。
  • 顺行股浅动脉与股总动脉使用血管闭合装置的总体并发症率和出血率无显著差异。
  • 临床选择装置时应考虑其个体安全性特征,而非仅依据入路部位。

核心结论

  • 不同血管闭合装置的总体汇总并发症率存在临床意义差异,趋势接近显著。
  • 不同血管闭合装置间出血风险存在显著差异,但可能受研究间异质性影响。
  • 顺行股浅动脉与股总动脉使用血管闭合装置的总体并发症和出血风险无差异。

研究设计与样本

  • 系统评价与汇总分析,检索MEDLINE和EMBASE从建库至2019年10月。
  • 纳入24项独特研究,共4124例血管闭合事件,涉及6种血管闭合装置。
  • 股总动脉3698例,股浅动脉426例;由两名独立评价者进行摘要筛选和数据提取。

主要发现

  • 股总动脉汇总并发症率范围0.9%(Mynx)至7.4%(Starclose)。
  • 股浅动脉汇总并发症率范围0%(Perclose)至10.1%(Starclose)。
  • 股总动脉出血并发症率范围0.4%(Mynx)至7.2%(Femoseal)(P = .01)。
  • 股浅动脉出血并发症率范围0%(Perclose)至6.4%(Starclose)(P = .03)。
  • 股总动脉与股浅动脉总体并发症率4.6% vs 5.8%(P = .56),出血率3.6% vs 3.6%(P = .98)。

临床怎么用

  • 临床选择血管闭合装置时需关注其个体出血风险差异,而非仅区分股总动脉或股浅动脉入路。
  • 顺行股浅动脉使用血管闭合装置未显示比股总动脉更高的总体并发症或出血风险。

局限性

  • 研究间存在显著异质性,限制了对装置间并发症率差异的确定性归因。
  • 部分装置比较的样本量有限,可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular closure devices (VCDs) have become a mainstay in endovascular interventions in recent years. On-label use only allows for retrograde interventions originating at the common femoral artery (CFA). However, off-label use in antegrade and/or superficial femoral artery (SFA) access has become more common in the treatment of peripheral arterial disease. Despite this, there is a paucity of comparative literature assessing individual VCD safety profiles and relative complication risks of CFA vs SFA applications. METHODS: MEDLINE and EMBASE systematic searches were performed from inception to October 2019 to identify studies assessing VCD use in antegrade CFA and SFA interventions. Abstract selection and data extraction were performed by two independent reviewers. Primary outcomes included bleeding-related complications, vessel occlusion or stenosis, embolization, pseudoaneurysm formation, or arteriovenous fistula formation. RESULTS: Twenty-four unique studies with 4124 vascular closure events via six unique VCDs were included (Angioseal, Exoseal, Femoseal, Glubran 2, Mynx, Starclose; 3698 CFA, 426 SFA). Pooled occurrence of all complications across closure devices used in the CFA and SFA ranged from 0.9% (Mynx) to 7.4% (Starclose) and 0% (Perclose) to 10.1% (Starclose), respectively, depending on VCD type. Clinically meaningful differences were identified between devices with a trend toward significance (P = .08 CFA, P = .07 SFA). Individual devices demonstrated a range of bleeding complication rates from 0.4% (Mynx) to 7.2% (Femoseal) for the CFA site and from 0% (Perclose) to 6.4% (Starclose) for the SFA site (P = .01 and P = .03, respectively). Significant heterogeneity between studies precludes definitive characterization of the device as cause for variations in bleeding complication rates. Pooled complication rates did not differ between the CFA and SFA arms (4.6% vs 5.8%, P = .56). Bleeding complication rates also did not differ between the CFA and SFA arms (3.6% vs 3.6%, P = .98). CONCLUSIONS: Clinically meaningful differences in overall pooled complications were identified between VCDs with a trend toward significance. Significant differences between VCDs exist with respect to bleeding risk. However, this must be interpreted with caution as these differences could be secondary to interstudy heterogeneity. Finally, no difference was identified between antegrade SFA and CFA VCD use with respect to overall complication and bleeding risks.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kennedy SA, Rajan DK, Bassett P, et al. Complication rates associated with antegrade use of vascular closure devices: a systematic review and pooled analysis. J Vasc Surg. 2020. PMID: 32950629. doi:10.1016/j.jvs.2020.08.133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。